JP2019513762A - 胆汁うっ滞及び線維症の処置方法 - Google Patents

胆汁うっ滞及び線維症の処置方法 Download PDF

Info

Publication number
JP2019513762A
JP2019513762A JP2018553113A JP2018553113A JP2019513762A JP 2019513762 A JP2019513762 A JP 2019513762A JP 2018553113 A JP2018553113 A JP 2018553113A JP 2018553113 A JP2018553113 A JP 2018553113A JP 2019513762 A JP2019513762 A JP 2019513762A
Authority
JP
Japan
Prior art keywords
group
fibrosis
compound
amino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513762A5 (https=
Inventor
デュベルネ，マチュー
ウォルクザック，ロベール
ドゥラタイユ，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Publication of JP2019513762A publication Critical patent/JP2019513762A/ja
Publication of JP2019513762A5 publication Critical patent/JP2019513762A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018553113A 2016-04-11 2017-03-13 胆汁うっ滞及び線維症の処置方法 Pending JP2019513762A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16305428.1 2016-04-11
EP16305426 2016-04-11
EP16305428 2016-04-11
EP16305426.5 2016-04-11
PCT/EP2017/055881 WO2017178174A1 (en) 2016-04-11 2017-03-13 Methods of treatment of cholestasis and fibrosis

Publications (2)

Publication Number Publication Date
JP2019513762A true JP2019513762A (ja) 2019-05-30
JP2019513762A5 JP2019513762A5 (https=) 2020-04-02

Family

ID=58261675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553113A Pending JP2019513762A (ja) 2016-04-11 2017-03-13 胆汁うっ滞及び線維症の処置方法

Country Status (4)

Country Link
US (1) US20170290814A1 (https=)
EP (1) EP3442952A1 (https=)
JP (1) JP2019513762A (https=)
WO (1) WO2017178174A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
WO2018167103A1 (en) 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
CN110575540B (zh) * 2018-06-07 2021-11-02 中山大学附属第六医院 Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途
JP7631217B2 (ja) 2019-04-10 2025-02-18 ジェンフィット 式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN112480104B (zh) * 2019-09-11 2024-06-18 绍兴君科臻元医药科技有限公司 硝唑尼特衍生物及其医药用途
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504255A (ja) * 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ａｔｐ結合カセットトランスポーターの調節因子
JP2009513563A (ja) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
JP2009522371A (ja) * 2006-01-09 2009-06-11 ロマーク ラボラトリーズ エル．シー． ウイルス性肝炎の処置
JP2013536259A (ja) * 2010-08-27 2013-09-19 カルシメディカ，インク． 細胞内カルシウムを調節する化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
WO2002051442A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1971594A2 (en) * 2005-11-21 2008-09-24 Biogen Idec MA Inc. Substituted pyrazalones
US8455658B2 (en) * 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
WO2013059677A1 (en) * 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9512116B2 (en) * 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2017006083A (es) * 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
US20190070154A1 (en) * 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
JP6894923B2 (ja) * 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
US11033534B2 (en) * 2017-01-27 2021-06-15 Genfit Pharmaceutical compositions for combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504255A (ja) * 2003-09-06 2007-03-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ａｔｐ結合カセットトランスポーターの調節因子
JP2009513563A (ja) * 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
JP2009522371A (ja) * 2006-01-09 2009-06-11 ロマーク ラボラトリーズ エル．シー． ウイルス性肝炎の処置
JP2013536259A (ja) * 2010-08-27 2013-09-19 カルシメディカ，インク． 細胞内カルシウムを調節する化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMRA S BLANCHARD: "GIARDIASIS AND CRYPTOSPORIDIOSIS - RECENT LITERATURE WITH A FOCUS ON NITAZOXANIDE", PEDIATRICS & THERAPEUTICS, vol. VOL:5, NR:4, JPN5019002870, 2015, pages 1 - 9, ISSN: 0004421957 *

Also Published As

Publication number Publication date
EP3442952A1 (en) 2019-02-20
US20170290814A1 (en) 2017-10-12
WO2017178174A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
JP2019513762A (ja) 胆汁うっ滞及び線維症の処置方法
US11524930B2 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
KR102431257B1 (ko) 담즙정체성 및 섬유증 질환의 치료 방법
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
JP2018188478A (ja) 肝疾患を処置する方法
JP2022504601A (ja) Ｍｓｔ１キナーゼ阻害剤及びその使用
EP3573614B1 (en) Pharmaceutical compositions for combination therapy
CA3054103A1 (en) Pharmaceutical compositions for combination therapy
CN113272298B (zh) 用于治疗呼吸系统疾病的化合物和组合物
AU2014230583B2 (en) Guanidinobenzoic acid ester compound
KR20180100373A (ko) 아스코클로린 유도체 및 ampk 활성제로서의 이의 용도
JP6843061B2 (ja) 疾患治療のための縮合二環化合物
US11400078B2 (en) Methods of treatment for cholestatic and fibrotic diseases
AU2021378944A1 (en) Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer
WO2014082592A1 (zh) 神经氨酸苷酶抑制剂的前药及其组合物和用途
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor
HK40121453A (zh) 用於治疗纤维化的磷酸甘油酸脱氢酶抑制剂
CN116887836A (zh) 用于治疗癌症的metap2抑制剂和cdk4/6抑制剂的组合
HK40016471B (en) Pharmaceutical compositions for combination therapy
HK40016471A (en) Pharmaceutical compositions for combination therapy
HK1220440B (en) Substituted aromatic compounds
NZ785186A (en) Methods of treatment for cholestatic and fibrotic diseases
JP2016515605A (ja) 抗アレルギー活性を有する新規なカルコン誘導体類

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220204

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220222

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220524